Other substances

Montelukast

A leukotriene receptor antagonist.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Montelukast is a leukotriene receptor antagonist used for prophylaxis and treatment of asthma, exercise-induced bronchoconstriction, and seasonal allergic rhinitis (DrugBank).

Montelukast on PubChem
Montelukast on Wikipedia

Marketed as

MONTELUKAST SODIUM (MONTELUKAST SODIUM); SINGULAIR; MONTAIR

CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server	in silico	4.55	Predicted to bind a SARS-CoV-2 protein structural feature.	Aug/11/2020
Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection Protein factor Small molecule Antibody In silico	in silico (machine learning)	13.49	Considered by the authors to be among the most relevant drugs identified in a machine-learning algorithm-based screening of compounds which considers causal protein-protein interactions, known drug targets, and specific signalling circuits in <a href=	Dec/11/2020
Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19 3CLpro Small molecule In silico	in silico	2.80	Predicted to bind SARS-CoV-2 3C-like protease with A191V mutation.	Feb/23/2021
Colchicine, aspirin, and montelukast – A case of successful combined pharmacotherapy for adult multisystem inflammatory syndrome in COVID-19 Small molecule Case report	A patient		Systematic clinical improvement was observed in a patient following the treatment initiation using colchicine, montelukast, and acetylsalicylic acid. Sample size: 1. Dosage: 10 mg daily.	Nov/30/2020

AI-suggested references

Link	Publication date
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.	Mar/16/2021
Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.	Aug/02/2021
Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: a multicenter, open-label, randomized controlled trial.	May/11/2022
As a potential treatment of COVID-19: Montelukast	Nov/15/2021
Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity	Dec/01/2020
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast	May/27/2020
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2	Mar/24/2022
Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol	Jan/06/2022
Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2.	Jun/28/2020
Levocetirizine and montelukast in the COVID-19 treatment paradigm.	Dec/15/2021
Colchicine, Aspirin, and Montelukast - A Case of Successful Combined Pharmacotherapy for Adult Multisystem Inflammatory Syndrome in COVID-19	Nov/30/2020
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic	Apr/27/2022
Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.	Apr/07/2021
Real-Life Benefit of Omalizumab in Improving Control of Bronchial Asthma During COVID-19 Pandemic.	Aug/17/2021
Montelukast in hospitalized patients diagnosed with COVID-19	Mar/04/2021
Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.	Feb/10/2021
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays	May/05/2021
Montelukast Inhibits Platelet Activation Induced by Plasma From COVID-19 Patients	Feb/08/2022
3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found?	Jun/28/2021
Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19	Jan/04/2022
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing	Jan/29/2022
The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies	Dec/30/2021
Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.	Apr/13/2021
Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials.	Mar/29/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04389411	The COvid-19 Symptom MOntelukast Trial	Not yet recruiting	Phase 3	Oct/01/2020	Dec/01/2021
Alternative id - 443807 Interventions - Drug: Montelukast 10mg Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 600 Age - 40 Years and older (Adult, Older Adult) Outcome measures - Emergency Room Visits and Hospitalizations\|Emergency room visit count\|Hospitalization admission count\|Time to ER Visit\|Time to hospitalization\|All-cause mortality\|Inpatient Length of stay\|Time to ICU admission\|Time to intubation\|Time to other serious COVID-19 complications
NCT05094596	Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19	Not yet recruiting	Phase 4	Oct/22/2021	Jan/22/2022
Alternative id - ATATURK-BUGRA-001 Interventions - Drug: Standart treatment group\|Drug: Montelukast sodium 10 mg treatment\|Drug: Montelukast sodium 20 mg treatment Study type - Interventional Study results - No Results Available Locations - Ataturk University, Erzurum, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 180 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Pulmonary function test
NCT04714515	Montelukast - a Treatment Choice for COVID-19	Completed		Feb/20/2020	Apr/20/2020
Alternative id - 01032020-7 Interventions - Drug: Montelukast\|Drug: Hydroxychloroquine\|Drug: Ivermectin Study type - Observational Study results - No Results Available Locations - Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China, Shanghai, China\|Shaukat Khanum Memorial Cancer Hospital & Research Centre, Johar Town, Lahore, Pakistan, Lahore, Punjab, Pakistan Study designs - Observational Model: Cohort\|Time Perspective: Retrospective Enrollment - 150 Age - 20 Years to 80 Years (Adult, Older Adult) Outcome measures - Patients admittance to ICU\|Length of total stay at the hospital\|Alleviating the symptoms of COVID-19\|Interleukin levels
NCT04718285	Investigation the Effect of Montelukast in COVID-19	Not yet recruiting	Phase 2	Jan/30/2021	May/30/2021
Alternative id - MON786.168.1 Interventions - Drug: Montelukast Oral Tablet\|Drug: Montelukast plus Favicovir (Favipiravir)\|Drug: Favicovir (Standard Treatment) Study type - Interventional Study results - No Results Available Locations - Bahcesehir University, School of Medicine, Department of Biophysics,, Istanbul, Turkey Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 380 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Hospitalized patient rates\|Emergency room visit rates of patients\|Time to emergency room visit\|Time to hospitalization\|Inpatient length of stay\|Time to ICU admission\|Time to intubation\|Mortality rate\|Family members rates with PCR positive test results\|Number/characteristics of AEs and SAEs\|Changes in blood pressure from baseline\|Changes in pulse from baseline\|Changes in respiratory rate from baseline\|Changes in fever from baseline\|Changes in oxygen saturation from baseline
NCT04695704	Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:	Not yet recruiting	Phase 3	Apr/01/2021	Dec/31/2022
Alternative id - 4R21/006 Interventions - Drug: Montelukast\|Other: placebo Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 284 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - COP Assessment Test Scale (CAT)\|1min sit-to-stand test\|O2 desaturation\|Visual Analogical Scale (VAS)\|All-cause mortality\|Number of visits to primary care\|Number of visits to the emergency room\|Number of hospital admissions.\|Medication side effects\|Days of sick leave\|Factors of inflamatory and prothrombotic processes: D-Dimer, N-terminal prohormone of brain natriuretic peptide (NT Pro-BNP), C-reactive protenin and Antinuclear antibodies (ANA)

Export (.csv)